Skip to main content
OpenTrials
Completed

NCT Number: NCT02412488

Reveal LINQ™ In-Office 2 (RIO2) Study International

The purpose of the RIO 2 International study is to provide clinical and economic evidence to support moving the LINQ™ insertion procedure outside these traditional locations within the hospital, referred to as "out-of-cathlab".

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The traditional location of the LINQ™ insertion procedure is the catheterization laboratory, electrophysiology laboratory, or operating room. The purpose of the RIO 2 International study is to provide clinical and economic evidence to support moving the LINQ™ insertion procedure outside these traditional locations within the hospital, referred to as "out-of-cathlab".

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is indicated for continuous arrhythmia monitoring with a Reveal LINQ™ Insertable Cardiac Monitor (ICM)
  • Patient is at least 18 years of age or older if required by local regulations
  • Patient is willing to undergo ICM insertion procedure outside of the cathlab, operating room, or EP lab setting with only local anesthetic
  • Patient is willing and able to provide consent and authorize the use and disclosure of health information
  • Patient is willing and able to comply with the elements of the clinical investigation plan including the required follow-up

Exclusion criteria

  • Patient has unusual thoracic anatomy or scarring at the insertion site which may adversely affect the success of the insertion procedure
  • Patient has reduced immune function or is otherwise at high risk for infection per physician discretion
  • Current therapy with immunosuppressive agents or chronic steroid use e.g. Prednisone greater than 20mg per day
  • Patient requires hemodialysis
  • Patient with active malignancy or history of chemotherapy or radiation treatment
  • Patient has had a recent (within 30 days) or an active infection including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia
  • Patient has had major surgery (in the past 6 months) Patient has undergone a procedure which required central venous or intra-arterial access (e.g. AF/VT ablation, EP study, coronary angiography) within the last 3 months or is scheduled for such a procedure while enrolled in the study
  • Prior history of surgical infection, prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months
  • Patient has a central venous port, an atrio-venous fistula, or a prosthetic valve
  • Patient requires conscious or moderate sedation to receive LINQ™
  • Patient already has an inserted or implanted loop recorder
  • Patient is implanted or indicated for implant with a pacemaker, ICD, CRT device
  • Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager
  • Patient's life expectancy is less than 6 months
  • Patient is legally incapable of giving consent
  • Patient is pregnant* *Note: Possible pregnancy will be assessed by the physician asking the patient; a pregnancy test is not required

Treatment and study plan

Out of cathlab insertion

Other

Insertion of the Reveal LINQ device in the "out-of-cathlab" setting (out of the operating room, cardiac catheterization or electrophysiology laboratory).

Primary outcomes

  1. Number of Participants With Untoward Events

    Time frame: 3 months

    An untoward event is a composite endpoint defined as a LINQTM or LINQTM insertion procedure related complication OR an unsuccessful LINQTM insertion procedure, where a LINQTM or LINQTM insertion procedure related complication is defined as an adverse event related to the LINQTM or a LINQTM insertion procedure resulting in:

    • Death
    • Termination of significant device function
    • Invasive intervention (e.g. includes LINQTM revision/explant for reasons other than diagnosis of underlying condition, intravenous drug administration)

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure

Industry

Registry information

Official study title

Reveal LINQ™ In-Office 2 (RIO2) International Study

Acronym: RIO2

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 9, 2015
Registry last updated
Feb 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.